Bio-Rad Laboratories, Inc. ( BIO ) Nowojorska Giełda Papierów Wartościowych

Cena: 303.97 ( 6.64% )

Aktualizacja 08-22 21:59
Nowojorska Giełda Papierów Wartościowych
Branża: Medical - Devices
Finanse
Rachunek zysków i strat
Bilans
Przepływy pieniężne
Prognozy
Statystyki
Dywidendy
Rekomendacje
Modele wyceny
Wskaźniki
Analiza techniczna

Notowania:

Opis firmy:

Bio-Rad Laboratories, Inc. Produkuje i dystrybuuje badania nauki o życiu i kliniczne produkty diagnostyczne w Stanach Zjednoczonych, Europie, Azji, Kanadzie i Ameryce Łacińskiej. Firma działa poprzez segmenty nauki o życiu i diagnostyce klinicznej. Segment nauki o życiu rozwija, produkuje i sprzedaje szereg odczynników, aparatu i instrumentów laboratoryjnych, które są stosowane w technikach badawczych, procesach produkcyjnych biofarmaceutycznych i systemach testowania żywności. Koncentruje się na wybranych segmentach rynku nauk przyrodniczych w proteomice, genomice, produkcji biofarmaceutycznej, biologii komórkowej i bezpieczeństwie żywności. Ten segment obsługuje uniwersytety i szkoły medyczne, organizacje badań przemysłowych, agencje rządowe, producentów farmaceutycznych, badaczy biotechnologii, producentów żywności i laboratoria testowania żywności. Segment diagnostyki klinicznej projektuje, produkuje, sprzedaje i wspiera systemy testowe, systemy informatyczne, zestawy testowe i wyspecjalizowane kontrole jakości dla laboratoriów klinicznych na rynku diagnostycznym. Ten segment oferuje odczynniki, instrumenty i oprogramowanie, które dotyczą określonych nisz na rynku testów diagnostycznych in vitro. Sprzedaje swoje produkty do laboratoriów referencyjnych, szpitalnych laboratoriów, stanowych noworodków, laboratoriów biurowych lekarzy i laboratoriów transfuzji. Ponadto firma oferuje produkty i systemy do oddzielenia złożonych materiałów chemicznych i biologicznych, a także identyfikacji, analizy i oczyszczania komponentów. Firma oferuje swoje produkty za pośrednictwem swoich bezpośrednich sił sprzedaży, a także dystrybutorów, agentów, brokerów i sprzedawców. Bio-Rad Laboratories, Inc. został założony w 1952 roku i ma siedzibę w Hercules w Kalifornii.

Informacje o spółce:
Sektor: Zdrowie
Branża: Medical - Devices
Zatrudnienie: 7 700
Giełda: Nowojorska Giełda Papierów Wartościowych
Ilość akcji w obrocie: 84.4798
Ilość akcji: Brak danych
Debiut giełdowy: 1980-02-27
WWW: https://www.bio-rad.com
CEO: Mr. Norman D. Schwartz
Adres: 1000 Alfred Nobel Drive
Siedziba: 94547 Hercules
ISIN: US0905722072
Wskaźniki finansowe
Kapitalizacja (USD) 8 226 182 958
Aktywa: 10 603 472 000
Cena: 303.97
Wskaźnik Altman Z-Score: 3.1
Stabilny (niskie ryzyko bankructwa)
Dywidenda: 0
P/E: 27.4
Ilość akcji w obrocie: 84%
Średni wolumen: 342 262
Ilość akcji 27 062 483
Wskaźniki finansowe
Przychody TTM 2 580 209 000
Zobowiązania: 3 115 613 000
Przedział 52 tyg.: 211.43 - 387.99
Piotroski F-Score: 6
Umiarkowany (średnia jakość finansowa)
EPS: 11.1
P/E branży: 29.9
Beta: 0.936
Raport okresowy: 2025-10-29
WWW: https://www.bio-rad.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Mr. Michael Crowley Executive Vice President of Global Commercial Operations 974 938 1962
Dr. Andrew J. Last Ph.D. Executive Vice President & Chief Operating Officer 682 294 1960
Mr. Norman D. Schwartz Chairman, Chief Executive Officer & President 1 252 341 1950
Ms. Colleen Corey Executive Vice President of Global Human Resources 0 1962
Lee Boyd Senior Vice President of Global Commercial Operations - Asia Pacific 0 0
Mr. Roop K. Lakkaraju Executive Vice President & Chief Financial Officer 0 1971
Courtney C. Enloe Executive Vice President, General Counsel & Secretary 0 0
Ms. Tania DeVilliers Senior Director, Corporate Controller & Interim Principal Accounting Officer 0 1974
Matthew Werner Senior Vice President and Chief Compliance & Privacy Officer 0 0
Mr. Yong Chung Vice President of Investor Relations 0 0
Lista ETF z ekspozycją na akcje Bio-Rad Laboratories, Inc.
Symbol ETF Ilość akcji Wartość
VCIT 24 659 000 22 717 791
VCSH 8 824 000 8 653 986
BIV 6 605 000 6 085 040
BSV 3 740 000 3 667 940
SCHI 3 490 000 3 225 589
IJH 627 687 151 868 832
VDCA.L 550 000 539 403
VUSC.L 550 000 408 754
VUSC.DE 550 000 472 355
VSCA.L 550 000 408 754
VDUC.L 550 000 539 403
VB 460 061 111 021 920
VBR 293 437 70 812 216
VCPA.L 240 000 167 552
VUCP.L 240 000 167 552
VDPA.L 240 000 221 106
VUCP.DE 240 000 193 623
VGPA.L 240 000 221 106
VDCP.L 240 000 221 106
VUCE.DE 240 000 193 623
VAGS.L 200 000 196 146
VAGP.L 200 000 196 146
V3GS.L 150 000 138 191
V3GP.L 150 000 138 191
MDY 142 474 35 632 576
DFAT 126 465 30 598 206
IJJ 106 890 25 862 023
SCHJ 100 000 97 970
GCOR 100 000 93 173
SPMD 85 207 21 445 124
DFSV 83 434 20 186 856
IWR 70 492 17 055 456
VHT 60 708 14 650 054
FNDA 57 942 14 268 921
DFAS 50 797 12 290 334
SCHM 49 342 12 204 850
XT 47 771 11 558 197
IWD 44 090 10 667 662
DFAC 40 235 9 734 858
MDYV 31 764 8 040 654
IWS 29 475 7 131 531
SCHG 29 133 7 288 167
IVOO 27 394 6 610 720
HEAL.L 26 942 6 518 585
DRDR.L 26 942 4 933 786
2B78.DE 26 942 5 702 458
SPY4.L 25 160 6 292 013
SPY4.DE 25 160 5 509 915
ITOT 24 004 5 807 857
SCHX 18 317 4 566 924
DFUV 17 069 4 129 844
IUSV 15 226 3 683 928
IWB 14 401 3 484 364
IVOV 13 803 3 330 939
JHMM 13 290 3 411 277
USVM 12 950 3 133 252
IYH 11 124 2 691 360
SCHB 10 744 2 676 740
VONV 9 588 2 313 776
BBMC 9 189 2 223 278
FSMD 8 592 2 175 752
FHLC 8 250 2 089 147
PRF 6 238 1 559 999
IWV 5 278 1 276 908
ESML 4 588 1 147 367
SMMD 4 582 1 145 866
ESGV 4 229 1 020 542
DFAU 4 215 1 019 819
RWK 3 747 937 049
AVUS 3 663 916 043
SPTM 3 505 877 938
EZM 3 406 824 081
VONE 3 005 725 166
ISCG 2 998 725 482
HTEC 2 835 0
PTMC 2 610 631 489
SGSU.L 2 599 475 858
QVMM 2 513 628 451
XMC.TO 2 445 844 323
SXRG.DE 2 433 514 984
CUSS.L 2 433 588 688
CUS1.L 2 433 445 566
CSUSS.MI 2 433 514 984
IU0C.SW 2 420 475 858
EQAL 2 416 604 193
IU0E.DE 2 248 475 858
DI27.PA 2 213 468 316
XJH 2 024 506 161
SUSU.L 1 967 475 858
IU0A.SW 1 967 475 858
SNAV.DE 1 967 416 281
IJH.AX 1 894 732 923
ZPRV.DE 1 814 346 042
USSC.L 1 814 395 161
SUOP.L 1 788 327 521
DCOR 1 729 418 331
XMH.TO 1 625 561 214
36BA.DE 1 547 327 521
VTHR 1 454 350 879
MOTE 1 448 350 343
PEXL 1 425 344 778
SCHK 1 422 354 358
CRHG.L 1 405 257 338
SAEF 1 220 303 998
36B7.DE 1 216 257 338
BLES 1 160 280 662
DFSU 1 139 275 581
TILT 1 078 260 822
6AQQ.DE 943 205 422
HNDX.DE 943 205 422
ANXU.L 943 234 521
ANX.PA 943 205 422
ANXG.L 943 17 771 953
ISCB 930 225 072
SUOP.L 920 168 533
KONG 867 0
XUU.TO 865 298 824
IYY 853 206 316
VLU 846 212 761
DTEC.L 809 151 012
DRUP.DE 809 174 552
UNIC.L 809 199 277
36BA.DE 796 168 533
PTL 769 186 059
JHML 740 189 943
MVV 732 177 107
IUS 730 182 558
SUOA.AS 697 168 533
5UOA.DE 697 147 432
GUSA 696 176 136
IUAE.L 562 118 964
AVMC 521 130 291
FNDB 460 109 555
ICBU.L 451 109 050
SXRF.DE 451 95 397
V3AB.L 420 76 805
V3AA.L 420 101 354
V3AL.L 420 101 354
AEGG.L 383 70 183
SHIR.SW 357 70 183
DXUV 355 85 892
AEGE.MI 332 70 183
MIDU 324 78 391
AGGE.AS 290 70 183
AVLC 287 71 772
GVUS 276 69 847
JUST 177 44 793
ICBU.L 174 42 109
SXRF.DE 174 36 837
MDEV 160 39 275
HELX 158 39 512
AUEM.PA 155 38 547
AUEG.L 155 2 921 159
AUEM.L 155 38 547
AMEM.DE 155 33 765
AEEM.MI 155 33 765
AEEM.PA 155 33 765
USFM.L 136 33 922
USUE.DE 136 33 922
XBAL.TO 134 46 317
WDNA.L 133 31 642
WBIO.L 133 31 642
BMED 129 31 260
XUH.TO 128 31 942
AVSU 126 31 510
IHCB.AX 123 17 598
R1VL.L 118 28 509
UMDD 112 27 098
STXM 110 26 614
XBAL.TO 81 10 563
CBUG.DE 69 14 657
EWSA.AS 69 16 755
XGRO.TO 65 8 454
APEX.L 65 16 165
LASI.DE 65 14 159
APX.PA 65 14 159
WDNA 65 15 726
STXV 61 14 758
XTR.TO 51 4 962
MIDE 49 12 253
AMEQ.DE 45 9 802
QCEU.PA 45 9 802
STXG 22 5 322
ACWI.PA 19 4 138
LYY0.DE 19 4 138
ACWU.L 19 4 725
ACWL.L 19 358 077
XSC.TO 17 1 666
LDCU.L 10 97 955
XTR.TO 5 1 292
MMTM 2 499
6PSA.DE 0 98 567
PXS.TO 0 7 027
PSRF.L 0 8 544 937
IGDA.L 0 92 970
IE00BN4Q0370.SG 0 0
PRUS.L 0 112 494
DWSH -470 -113 716
Wiadomości dla Bio-Rad Laboratories, Inc.
Tytuł Treść Źródło Aktualizacja Link
Bio-Rad (BIO) International Revenue Performance Explored Review Bio-Rad's (BIO) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock. zacks.com 2025-02-26 12:15:38 Czytaj oryginał (ang.)
BLUEBIRD BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of bluebird bio, Inc. - BLUE NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of bluebird bio, Inc. (NasdaqGS: BLUE) to Carlyle Group and SK Capital Partners, LP. Under the terms of the agreement, bluebird shareholders will receive $3.00 per share in cash and a contingent value right per share, entitling the holder to a payment of $6.84 in cash per contingent value right if bluebird's curr. businesswire.com 2025-02-24 21:22:00 Czytaj oryginał (ang.)
BIO Stock Might Rise Following the Offer to Acquire Stilla Bio-Rad offers to acquire all equity interests of Stilla Technology. The acquisition is expected to complement Bio-Rad's existing digital PCR portfolio. zacks.com 2025-02-18 10:30:40 Czytaj oryginał (ang.)
BIO Q4 Earnings and Revenues Miss Estimates, Stock Down Aftermarket Bio-Rad witnesses growth across the Clinical Diagnostics segment in the fourth quarter, primarily driven by an increased demand for quality control and blood typing products. zacks.com 2025-02-14 17:01:11 Czytaj oryginał (ang.)
Bio-Rad Laboratories, Inc. (BIO) Q4 2024 Earnings Call Transcript Bio-Rad Laboratories, Inc. (NYSE:BIO ) Q4 2024 Earnings Conference Call February 13, 2025 5:00 PM ET Company Participants Edward Chung - Vice President of Investor Relations Jon DiVincenzo - President & Chief Operating Officer Roop Lakkaraju - Executive Vice President & Chief Financial Officer Norman Schwartz - Chairman of the Board, President & Chief Executive Officer Conference Call Participants Dan Leonard - UBS Brandon Couillard - Wells Fargo Jack Meehan - Nephron Research Conor McNamara - RBC Capital Markets Tycho Peterson - Jefferies Operator Thank you for standing by. My name is Prila [ph] and I will be your conference operator today. seekingalpha.com 2025-02-14 01:45:02 Czytaj oryginał (ang.)
Bio-Rad Laboratories (BIO) Misses Q4 Earnings and Revenue Estimates Bio-Rad Laboratories (BIO) came out with quarterly earnings of $2.90 per share, missing the Zacks Consensus Estimate of $2.93 per share. This compares to earnings of $3.10 per share a year ago. zacks.com 2025-02-13 20:46:11 Czytaj oryginał (ang.)
Bio-Rad Reports Fourth-Quarter and Full-Year 2024 Financial Results HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full year ended December 31, 2024. Norman Schwartz, Bio-Rad's Chairman and Chief Executive Officer, commented: “Bio-Rad demonstrated resilience and adaptability in 2024. While the biopharma headwinds dampened our Life Science segment results, our Clinical Diagnostics business. businesswire.com 2025-02-13 18:20:00 Czytaj oryginał (ang.)
Bio-Rad Offers to Acquire Digital PCR Developer Stilla Technologies HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company has entered into a binding offer to purchase all equity interests in Stilla Technologies (“Stilla”). The acquisition remains subject to consultation with relevant employee representatives, regulatory approvals, and other customary closing conditions, and is expected to close by the end of the third quart. businesswire.com 2025-02-13 18:15:00 Czytaj oryginał (ang.)
Oncocyte Prices $29.1 Million Equity Offering IRVINE, Calif., Feb. 10, 2025 – PRISM MediaWire – Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that it has entered into securities purchase agreements with existing investors for a registered direct offering (“Registered Direct Offering”) and concurrent private placement (“PIPE Offering”). prismmediawire.com 2025-02-10 10:30:04 Czytaj oryginał (ang.)
Processa Pharmaceuticals to Present at the 2025 BIO CEO & Investor Conference HANOVER, Md., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation cancer therapies with improved efficacy and safety, today announced its participation in the 2025 BIO CEO & Investor Conference being held February 10-11, 2025, at the New York Marriott Marquis. globenewswire.com 2025-02-07 10:00:00 Czytaj oryginał (ang.)
Earnings Preview: Bio-Rad Laboratories (BIO) Q4 Earnings Expected to Decline Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com 2025-02-06 13:06:03 Czytaj oryginał (ang.)
Tonix Pharmaceuticals to Participate in the 2025 BIO CEO & Investor Conference CHATHAM, N.J., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals, will present at the BIO CEO & Investor Conference on February 10, 2025, at 1:45 p.m. ET in New York City. globenewswire.com 2025-02-05 09:00:00 Czytaj oryginał (ang.)
Has BioRad Laboratories (BIO) Outpaced Other Medical Stocks This Year? Here is how Bio-Rad Laboratories (BIO) and Certara, Inc. (CERT) have performed compared to their sector so far this year. zacks.com 2025-02-04 12:45:38 Czytaj oryginał (ang.)
Protalix BioTherapeutics to Participate in the 2025 BIO CEO & Investor Conference Corporate presentation scheduled for Tuesday, February 11, 2025 at 10:15 AM EST CARMIEL, Israel , Feb. 4, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell based protein expression system, today announced that it will attend and present at the 2025 BIO CEO & Investor Conference taking place February 10-11, 2025 at the New York Marriott Marquis in New York City. Management is scheduled to give a corporate overview at the BIO CEO & Investor Conference on Tuesday, February 11, 2025 at 10:15 AM EST at the Royale Room and will be available to participate in one-on-one partnering meetings with registered investors and other conference attendees. prnewswire.com 2025-02-04 08:50:00 Czytaj oryginał (ang.)
Lifecore Biomedical to Participate in 2025 BIO CEO & Investor Conference CHASKA, Minn., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate at the 2025 BIO CEO & Investor Conference. The conference will take place February 10-11, 2025, in New York, NY. globenewswire.com 2025-02-03 09:00:00 Czytaj oryginał (ang.)
Reviva to Participate in the 2025 BIO CEO & Investor Conference CUPERTINO, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in a panel discussion at the 2025 BIO CEO & Investor Conference, taking place February 10-11, 2025, in New York, NY. globenewswire.com 2025-01-30 10:00:00 Czytaj oryginał (ang.)
Bio-Rad to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025 HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the fourth quarter and full year of 2024 on Thursday, February 13, 2025, following the close of the market. Management will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day. To participate, dial (800) 715-9871 within the U.S. or (646) 307-1963 o. businesswire.com 2025-01-27 19:00:00 Czytaj oryginał (ang.)
Wyoming Department of Education Chooses BIO-key PortalGuard IDaaS Platform to Secure Identity and Access Management for Critical Systems and Data BKYI: Wyoming Department of Education Chooses BIO-key PortalGuard IDaaS Platform to Secure Identity and Access Management for Critical Systems and Data. globenewswire.com 2025-01-27 09:59:00 Czytaj oryginał (ang.)
Three Higher Education Customers with 30,000+ Users Migrate to BIO-key's PortalGuard IDaaS Cloud Platform for Streamlined Operations and Enhanced Access Management BKYI: 3 Higher-Ed Customers with 30,000+ Users Migrate to BIO-key's PortalGuard IDaaS Cloud Platform for Streamlined Operations & Enhanced Access Mgt. globenewswire.com 2025-01-21 09:58:00 Czytaj oryginał (ang.)
Why Bio-Rad Stock is an Apt Pick for Your Portfolio Right Now BIO's robust performance of the ddPCR platform and clinical diagnostics momentum bodes well for investors. zacks.com 2025-01-17 09:16:10 Czytaj oryginał (ang.)
Bio-Rad's Management to Host Investor Meetings at J.P. Morgan's 43rd Annual Healthcare Conference HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company's Chief Executive Officer Norman Schwartz, Chief Operating Officer Jon DiVincenzo, and Chief Financial Officer Roop K. Lakkaraju will host one-on-one meetings with analysts and investors during J.P. Morgan's 43rd Annual Healthcare Conference in San Francisco, CA, January 13-16, 2025. About Bio-Rad Bio-Ra. businesswire.com 2025-01-02 18:30:00 Czytaj oryginał (ang.)
New Jersey Based Biometric and Cyber Security Solutions Provider BIO-key to Present and Participate at DealFlow's Atlantic City Microcap Conference Jan. 29th and 30th New Jersey Based Biometric & Cyber Security Solutions Provider BIO-key (BKYI) to Present/Participate at DealFlow's Atlantic City Microcap Conf. 1/29 & 1/30 globenewswire.com 2025-01-02 10:30:00 Czytaj oryginał (ang.)
BIO-TECHNE TO PRESENT AT THE 43rd ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE MINNEAPOLIS , Dec. 20, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 10:30 a.m. prnewswire.com 2024-12-20 09:00:00 Czytaj oryginał (ang.)
BIO-TECHNE ANNOUNCES BIOTHERAPEUTIC CHARACTERIZATION STRATEGIC CO-MARKETING AND CO-PROMOTION AGREEMENT MINNEAPOLIS , Dec. 19, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a leader in automated platforms for biotherapeutic characterization, today announced a co-marketing and co-promotion agreement with Waters Corporation aimed at expanding the reach of advanced biotherapeutic characterization and development processes. The companies plan to combine their complementary expertise on charge separation (Bio-Techne's MauriceFlex™ System) and liquid chromatography mass spectrometry (BioAccord™ LC-MS System from Waters) to deliver innovative solutions that optimize workflows, improve precision, and accelerate development timelines. prnewswire.com 2024-12-19 09:00:00 Czytaj oryginał (ang.)
BIO-TECHNE ANNOUNCES NEW DISTRIBUTION AGREEMENT WITH MEDSANTEK TO EXPAND ACCESS TO PORTFOLIO ACROSS TURKEY MINNEAPOLIS , Dec. 12, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities today announced a partnership with MedSanTek. Under the agreement, MedSanTek becomes the distributor of Bio-Techne's R&D Systems, Novus, Tocris, Protein Simple, Advanced Cell Diagnostics (ACD), and Asuragen brands across Turkey. prnewswire.com 2024-12-12 09:00:00 Czytaj oryginał (ang.)
BIO-TECHNE LAUNCHES ESR1 MUTATION MONITORING ASSAY Company will showcase new assay at the upcoming San Antonio Breast Cancer Symposium MINNEAPOLIS , Dec. 10, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Asuragen, a Bio-Techne brand, launched a highly sensitive ESR1 mutation monitoring assay. ESR1 gene mutations are known to be linked to hormone receptor-positive (HR+) metastatic breast cancer. prnewswire.com 2024-12-10 09:00:00 Czytaj oryginał (ang.)
BIO-Key Responds to the Cry for Secure Authentication with New Passwordless Options at the 2024 Gartner® Identity & Access Management Summit: North America HOLMDEL, N.J., Dec. 09, 2024 (GLOBE NEWSWIRE) -- BIO-key® International, Inc. (NASDAQ: BKYI), an innovative provider of workforce and customer identity and access management (IAM) solutions for phoneless, tokenless, passwordless, and phishing-resistant authentication experiences, today announced that it was proud to be recognized in two Gartner reports in the past twelve months. globenewswire.com 2024-12-09 10:28:00 Czytaj oryginał (ang.)
BIO-key and Fiber Food Systems Inc. Collaborate to Enhance Security and Efficiency in the Food Tech Sector BIO-key (BKYI) & Fiber Food Systems Inc. Collaborate to Enhance Security & Efficiency in Food Tech Sector. Transaction Strengthens BIO-key's Balance Sheet. globenewswire.com 2024-12-02 10:29:00 Czytaj oryginał (ang.)
BIO-TECHNE TO PRESENT AT THE CITI 2024 GLOBAL HEALTHCARE CONFERENCE MINNEAPOLIS , Nov. 27, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer, will present at the Citi 2024 Global Healthcare Conference on Wednesday, December 4, 2024, at 3:15 p.m. EST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar. prnewswire.com 2024-11-27 09:00:00 Czytaj oryginał (ang.)
BIO-TECHNE ANNOUNCES NEW DISTRIBUTION AGREEMENT WITH LEADER LIFE SCIENCES MINNEAPOLIS , Nov. 20, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities today announced a partnership with Leader Life Sciences. Under the agreement, Leader Life Sciences becomes a distributor of Bio-Techne's portfolio across the Gulf Cooperation Council (GCC) countries, which include Bahrain, Oman, Qatar, Saudi Arabia, and United Arab Emirates. prnewswire.com 2024-11-20 09:00:00 Czytaj oryginał (ang.)
BIO-TECHNE AND ALZpath ANNOUNCE STRATEGIC PARTNERSHIP TO ADVANCE NEURODEGENERATIVE DISEASE RESEARCH MINNEAPOLIS , Nov. 18, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced a strategic partnership with ALZpath, Inc to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The collaboration leverages Bio-Techne's Ella™ fully automated, multiplexing immunoassay platform and ALZpath's proprietary pTau217 antibody to provide the Simple Plex Human Phospho-Tau (T217) ALZpath Assay. prnewswire.com 2024-11-18 09:00:00 Czytaj oryginał (ang.)
BIO-key Reports Q3'24 Revenue Rose 18% to $2.1M, Reduced Q3'24 Net Loss, and Improved Cash Position; Hosts Investor Call Tomorrow, Fri. Nov. 15th, 10am ET BIO-key (BKYI) Reports Q3'24 Revenue Rose 18% to $2.1M, Reduced Q3'24 Net Loss, Improved Cash Position; Hosts Conf. Call Tomorrow, Fri. Nov. 15th, 10am ET. globenewswire.com 2024-11-14 19:51:00 Czytaj oryginał (ang.)
BIO-TECHNE TO HIGHLIGHT NOVEL SOLUTIONS FOR CANCER AND CARRIER SCREENING AT AMP 2024 ANNUAL MEETING & EXPO Customers will present data from their use of novel assays and kits; company will host educational workshops and discussions for attendees MINNEAPOLIS , Nov. 14, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced its lineup of presentations and activities for the Association for Molecular Pathology (AMP) 2024 Annual Meeting & Expo, taking place November 19-23 in Vancouver, British Columbia. Asuragen, a Bio-Techne brand, will be exhibiting and showcasing its latest research products for breast cancer monitoring and carrier screening in booth #811. prnewswire.com 2024-11-14 09:00:00 Czytaj oryginał (ang.)
UPDATED: BIO-TECHNE ANNOUNCES IVDR CERTIFIED HEMATOLOGY CONTROLS AND CALIBRATORS R&D Systems Hematology Controls and Calibrators has completed the Class B Certification under the new European Union In Vitro Diagnostic Regulation This press release updates the IVDR Classification to Class B from the prior Class C.  MINNEAPOLIS , Nov. 11, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) has recently achieved In Vitro Diagnostic Regulation (IVDR) certification for its R&D Systems Hematology Controls and Calibrators. prnewswire.com 2024-11-11 19:47:00 Czytaj oryginał (ang.)
BIO-TECHNE ANNOUNCES IVDR CERTIFIED HEMATOLOGY CONTROLS AND CALIBRATORS R&D Systems Hematology Controls and Calibrators has completed the Class C Certification under the new European Union In Vitro Diagnostic Regulation MINNEAPOLIS , Nov. 11, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) has recently achieved In Vitro Diagnostic Regulation (IVDR) certification for its R&D Systems Hematology Controls and Calibrators. This certification confirms that the products comply with the regulations and guidelines set forth by the European Union for in-vitro diagnostic devices. prnewswire.com 2024-11-11 09:00:00 Czytaj oryginał (ang.)
BIO-TECHNE TO PRESENT AT INVESTOR CONFERENCES MINNEAPOLIS , Nov. 8, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it will present at the following investor conferences: UBS Global Healthcare Conference November 12, 2024 9:30 AM PST Stifel 2024 Healthcare Conference November 19, 2024 8:00 AM EST Stephens NASH 2024 Conference November 20, 2024 11:00 AM CST A live webcast of the presentations can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar. About Bio-Techne Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. prnewswire.com 2024-11-08 09:00:00 Czytaj oryginał (ang.)
Interpreting Bio-Rad (BIO) International Revenue Trends Examine the evolution of Bio-Rad's (BIO) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects. zacks.com 2024-11-04 12:22:49 Czytaj oryginał (ang.)
Tiziana Life Sciences to showcase breakthrough therapies at BIO-Europe 2024 Conference Tiziana Life Sciences Ltd (NASDAQ:TLSA) said it will participate in the upcoming BIO-Europe 2024 conference in Stockholm. The event will allow Tiziana to engage with industry leaders, potential collaborators, and investors, emphasizing its recent clinical advancements, particularly data from its combination study involving Ozempic, a GLP-1 agonist. proactiveinvestors.com 2024-11-01 18:31:20 Czytaj oryginał (ang.)
Tiziana Life Sciences to Participate in BIO-Europe 2024 to Discuss Recent Clinical Advancements, Including Positive GLP-1 Combination Study Data NEW YORK, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced its participation in the BIO-Europe 2024 conference, taking place November 4-6 in Stockholm, Sweden. As part of the conference's partnering meetings, Tiziana will engage with industry leaders, potential collaborators, and investors to discuss recent clinical progress, including data from its combination study involving Ozempic, a GLP-1 agonist. globenewswire.com 2024-11-01 15:00:00 Czytaj oryginał (ang.)
BIO Q3 Earnings and Revenues Surpass Estimates, Stock Up Aftermarket Bio-Rad witnesses growth across the Clinical Diagnostics segment in the third quarter, primarily driven by an increased demand for quality control and immunology products. zacks.com 2024-10-31 11:46:23 Czytaj oryginał (ang.)